Dr. Steven R. Bauer
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- New York College of Osteo Medicine of New York Institute of Technology (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 296
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: New York College of Osteo Medicine of New York Institute of Technology
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NY license 207738
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health Matthews Medical Center Matthews, NC
- Novant Health Ballantyne Medical Center Charlotte, NC
Medical groups
- Legacy Healthcare Services Inc (3,223 clinicians)
- Ballantyne Medical Associates PLLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 296
- Services billed
- 2,848
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 471 | 207 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 187 | 35 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 179 | 34 |
| Injection, dexamethasone sodium phosphate, 1 mg | 173 | 12 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 173 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 166 | 108 |
| Injection of drug or substance under skin or into muscle | 97 | 20 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 92 | 92 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 73 | 11 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 68 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 26 companies reported 99 payments worth $1,912 in total to this clinician.
| Novo Nordisk Inc | $477 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $261 |
| Pfizer Inc. | $187 |
| AbbVie Inc. | $165 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $120 |
| Amgen Inc. | $75.41 |
| Verity Pharmaceuticals Inc. | $75.06 |
| Lilly USA, LLC | $57.73 |
| Food and Beverage | $1,912 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $569,685 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
ModernaTX, Inc. · Completed · NCT05575492 - Phase 3 multicenter openlabel study to assess the longterm safety and tolerability of rimegepant for the acute treatment of migraine with or without aura in children and adolescents 6 to 18 years of age
Pfizer Inc. - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression
Merck Sharp & Dohme LLC - Phase 3 multicenter randomized doubleblind group sequential placebocontrolled study to assess efficacy and safety of rimegepant for the treatment of migraine with or without aura in children and adolescents 6 to 18 …
Pfizer Inc. - A phase 2B multicenter randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of onceweekly MET097 in adults with obesity or overweight and type 2 diabetes mellitus VESPER2
Pfizer Inc. - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
AstraZeneca Pharmaceuticals LP - A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma
Incyte Corporation - Study name not reported
Novo Nordisk As - Transmission Study household
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.